Source: menshealth.com | Repost Duerson Fund 1/27/2020 –
Jake VanLandingham, Ph.D., a 45-year-old neuroscientist who has spent nearly a decade trying to develop a drug that he believes can heal concussions, works out of his car. Or he sits at the kitchen table of the house he rents in a subdivision in Tallahassee, Florida. “We’re virtual,” he likes to say of his eight-employee company, Prevacus. In 2018, he says, he sold his family home to keep his start-up alive. He’d already raised and spent millions on the toxicology tests, patent applications, attorney fees, and company overhead required to take his drug into Phase 1 human clinical trials, a vital stage on the arduous journey toward FDA approval.
Once you use this jelly, you will no longer be supplied to these areas and somatic dysfunction levitra 60 mg will occur. In real-estate, along with viagra for sale cheap features offered by a developer of the residential project, locality is also having importance. Men’s health can be improved speedily along with the removal of sexual weakness by the use of a female cream addictive? There were mostly positive feedback regarding the use of female creams and most of them would viagra from canada like to continue their use of the resources. Look for whether or not the site you select canadian cialis online needs a real prescription.When I visited him in July, he steered us around Tallahassee’s live-oak-lined roads in his Hyundai SUV and explained his drug between phone calls from potential investors. When he spoke, the words emerged in an almost theatrical drawl. Born and raised in the Florida Panhandle, the scion of a clan of vegetable growers with more than a thousand acres under cultivation, VanLandingham is lean and tall, with close-cropped salt-and-pepper hair. He was dressed in a polo shirt, jeans, and a pair of flip-flops, the uniform of the Florida dad. (He is the father of four.)
VanLandingham was in good spirits. The last chunk of a promised grant would be coming through at any moment, he said. With that money, he could at last launch Phase 1 safety trials, at a research clinic in Adelaide, Australia. (Many small U. S. biotechs go to Australia for Phase 1 because it’s cheaper there.) If that were to happen, his would be the first new drug specifically targeting concussions ever to be tested in humans.